| scholarly article | Q13442814 |
| P50 | author | Kaushik Parsha | Q57562021 |
| P2093 | author name string | Wei Li | |
| Bing Yang | |||
| Yali Zhao | |||
| Sean I Savitz | |||
| Farhaan Vahidy | |||
| Peiman Hematti | |||
| Adrian P Gee | |||
| Patrick J Hanley | |||
| Osman Mir | |||
| April G Durett | |||
| Debra Bloom | |||
| Zhuyong Mei | |||
| Maria da Graca Cabreira-Hansen | |||
| Mariola Klis | |||
| R Brent Rice | |||
| P2860 | cites work | Multilineage potential of adult human mesenchymal stem cells | Q27860737 |
| Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement | Q27861120 | ||
| Mesenchymal stem cells in health and disease | Q29614296 | ||
| Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. | Q30167892 | ||
| The establishment of a bank of stored clinical bone marrow stromal cell products | Q33454406 | ||
| Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta | Q33855709 | ||
| Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System | Q33977993 | ||
| Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone | Q34066339 | ||
| Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method | Q34210598 | ||
| Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art | Q34271229 | ||
| Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases | Q34367266 | ||
| Translating research into clinical scale manufacturing of mesenchymal stromal cells | Q34557484 | ||
| The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments | Q34686955 | ||
| Treatment of inflammatory diseases with mesenchymal stem cells | Q34987147 | ||
| Mesenchymal stem cells for the treatment of diabetes | Q35976665 | ||
| Immunomodulatory properties of mesenchymal stromal cells | Q36896799 | ||
| Mesenchymal stem cells in hematopoietic stem cell transplantation | Q37396930 | ||
| Good manufacturing practices production of mesenchymal stem/stromal cells. | Q37804393 | ||
| Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures | Q38272362 | ||
| A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke | Q38485063 | ||
| Manufacturing mesenchymal stromal cells for phase I clinical trials | Q39431469 | ||
| Culture and Use of Mesenchymal Stromal Cells in Phase I and II Clinical Trials | Q41854522 | ||
| Evaluation of senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue, and umbilical cord tissue | Q44038136 | ||
| Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor | Q44589692 | ||
| Improved isolation and expansion of bone marrow mesenchymal stromal cells using a novel marrow filter device. | Q53124601 | ||
| GMP-Compliant Isolation and Expansion of Bone Marrow-Derived MSCs in the Closed, Automated Device Quantum Cell Expansion System | Q60628176 | ||
| CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury | Q73503153 | ||
| Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells | Q73664290 | ||
| T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression | Q81704121 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1048-1058 | |
| P577 | publication date | 2014-04-13 | |
| P1433 | published in | Cytotherapy | Q5201399 |
| P1476 | title | Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System | |
| P478 | volume | 16 |
| Q64083263 | A comprehensive characterisation of large-scale expanded human bone marrow and umbilical cord mesenchymal stem cells |
| Q34979619 | A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression |
| Q50432799 | Allogeneic cell therapy manufacturing: process development technologies and facility design options |
| Q47592957 | An Integrated Bioprocess for the Expansion and Chondrogenic Priming of Human Periosteum-Derived Progenitor Cells in Suspension Bioreactors. |
| Q61954919 | Biomanufacturing for clinically advanced cell therapies |
| Q38646797 | Challenges and opportunities in the manufacture and expansion of cells for therapy. |
| Q53636359 | Clinical-scale expansion of adipose-derived stromal cells starting from stromal vascular fraction in a single-use bioreactor: proof of concept for autologous applications. |
| Q37419366 | Culture expansion of adipose derived stromal cells. A closed automated Quantum Cell Expansion System compared with manual flask-based culture. |
| Q57069297 | Engineering mesenchymal stem cells to improve their exosome efficacy and yield for cell-free therapy |
| Q55515982 | GMP Production and Scale-Up of Adherent Neural Stem Cells with a Quantum Cell Expansion System. |
| Q51313339 | GMP-Compliant Expansion of Clinical-Grade Human Mesenchymal Stromal/Stem Cells Using a Closed Hollow Fiber Bioreactor. |
| Q41704260 | Hypoxic Three-Dimensional Scaffold-Free Aggregate Cultivation of Mesenchymal Stem Cells in a Stirred Tank Reactor. |
| Q97526464 | Influence of Microenvironment on Mesenchymal Stem Cell Therapeutic Potency: From Planar Culture to Microcarriers |
| Q52866935 | Isolation and Manufacture of Clinical-Grade Bone Marrow-Derived Human Mesenchymal Stromal Cells. |
| Q92480675 | Large-scale expansion and characterization of CD3+ T-cells in the Quantum® Cell Expansion System |
| Q35751032 | Large-scale production of lentiviral vector in a closed system hollow fiber bioreactor |
| Q33608418 | Manufacturing Differences Affect Human Bone Marrow Stromal Cell Characteristics and Function: Comparison of Production Methods and Products from Multiple Centers |
| Q52346923 | Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges. |
| Q26799475 | Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects |
| Q39045625 | Mesenchymal stromal cells with enhanced therapeutic properties |
| Q55110102 | Optimizing T Cell Expansion in a Hollow-Fiber Bioreactor. |
| Q26773103 | Patient-Specific Age: The Other Side of the Coin in Advanced Mesenchymal Stem Cell Therapy |
| Q92151854 | Preparing for cell culture scale-out: establishing parity of bioreactor- and flask-expanded mesenchymal stromal cell cultures |
| Q51371163 | Process automation in manufacturing of mesenchymal stromal cells. |
| Q36304988 | Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency. |
| Q51335986 | Stirred tank bioreactor culture combined with serum-/xenogeneic-free culture medium enables an efficient expansion of umbilical cord-derived mesenchymal stem/stromal cells. |
| Q38535126 | The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy |
| Q58615311 | Tolerising cellular therapies: what is their promise for autoimmune disease? |
Search more.